Nothing Special   »   [go: up one dir, main page]

ES2091018T3 - Procedimiento para la deteccion de enfermedades neoplasicas. - Google Patents

Procedimiento para la deteccion de enfermedades neoplasicas.

Info

Publication number
ES2091018T3
ES2091018T3 ES93916537T ES93916537T ES2091018T3 ES 2091018 T3 ES2091018 T3 ES 2091018T3 ES 93916537 T ES93916537 T ES 93916537T ES 93916537 T ES93916537 T ES 93916537T ES 2091018 T3 ES2091018 T3 ES 2091018T3
Authority
ES
Spain
Prior art keywords
detection
procedure
neoplastic diseases
detect
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93916537T
Other languages
English (en)
Inventor
Michael Philip Nova
Ana-Maria Gonzalez
J Andrew Baird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whittier Institute for Diabetes and Endocrinology
Original Assignee
Whittier Institute for Diabetes and Endocrinology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whittier Institute for Diabetes and Endocrinology filed Critical Whittier Institute for Diabetes and Endocrinology
Application granted granted Critical
Publication of ES2091018T3 publication Critical patent/ES2091018T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

PROCESOS PARA DETECTAR LA PRESENCIA DE ENFERMEDAD NEOPLASTICA. LOS PROCESOS COMPRENDEN LA DETECCION DE UN PRODUCTO ASOCIADO CON LA EXPRESION DE GENES QUE CODIFICAN LOS RECEPTORES DE PROTEINA PARA L FACTOR DE CRECIMIENTO DE FIBROBLASTO EN CELULAS O UN PRODUCTOS INDICATIVO DE NIVELES ELEVADOS DE UN RECEPTOR DE FACTOR DE CRECIMIENTO DE FIBROBLASTO EN UN FLUIDO CORPORAL. LA DETECCION SE PUEDE LLEVAR A CABO DE VARIAS MANERAS, INCLUIDA LA HIBRIDACION PARA DETECTAR LA PRESENCIA DE ARNM QUE CODIFICA UN RECEPTOR DE FACTOR DE CRECIMIENTO O ENSAYOS INMUNOLOGICOS PARA DETECTAR LA PRESENCIA DE PROTEINA RECEPTORA. TAMBIEN SE PREVEN KITS PARA REALIZAR LOS PROCESOS.
ES93916537T 1992-06-18 1993-06-14 Procedimiento para la deteccion de enfermedades neoplasicas. Expired - Lifetime ES2091018T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90064692A 1992-06-18 1992-06-18

Publications (1)

Publication Number Publication Date
ES2091018T3 true ES2091018T3 (es) 1996-10-16

Family

ID=25412867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93916537T Expired - Lifetime ES2091018T3 (es) 1992-06-18 1993-06-14 Procedimiento para la deteccion de enfermedades neoplasicas.

Country Status (10)

Country Link
US (1) US5670323A (es)
EP (1) EP0646182B1 (es)
AT (1) ATE141958T1 (es)
AU (1) AU686566B2 (es)
CA (1) CA2136439A1 (es)
DE (1) DE69304331T2 (es)
DK (1) DK0646182T3 (es)
ES (1) ES2091018T3 (es)
GR (1) GR3021817T3 (es)
WO (1) WO1994000599A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021813A1 (en) * 1993-03-17 1994-09-29 The Whittier Institute For Diabetes And Endocrinology Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
WO1999035159A1 (en) * 1998-01-08 1999-07-15 Brigham & Women's Hospital, Inc. Lymphoma/leukemia oncogene, oncoprotein and methods of use
EP1697420A2 (en) * 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
JO3469B1 (ar) 2009-05-05 2020-07-05 Amgen Inc طافرات fgf21 واستخداماتها
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
AR123306A1 (es) 2020-08-21 2022-11-16 Genzyme Corp Anticuerpos fgfr3 y métodos de uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE120497T1 (de) * 1988-05-09 1995-04-15 Univ Temple Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten.
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
EP0387777A3 (en) * 1989-03-15 1992-01-02 Takeda Chemical Industries, Ltd. Method for detecting and measuring fgf and for diagnosis of tumor
ATE179862T1 (de) * 1989-07-06 1999-05-15 Univ California Rezeptoren für fibroblasten-wachstumsfaktoren
DE69129070T2 (de) * 1990-09-19 1998-08-20 Roger Williams General Hospita Behandlung von tumorogenen pathophysiologischen zuständen durch verwendung von f4f-cytotoxinkonjugaten

Also Published As

Publication number Publication date
AU686566B2 (en) 1998-02-12
WO1994000599A3 (en) 1994-02-17
CA2136439A1 (en) 1994-01-06
DE69304331D1 (de) 1996-10-02
DK0646182T3 (da) 1996-09-16
ATE141958T1 (de) 1996-09-15
EP0646182A1 (en) 1995-04-05
GR3021817T3 (en) 1997-02-28
WO1994000599A2 (en) 1994-01-06
DE69304331T2 (de) 1997-01-16
AU4635493A (en) 1994-01-24
US5670323A (en) 1997-09-23
EP0646182B1 (en) 1996-08-28

Similar Documents

Publication Publication Date Title
Maul et al. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase.
FI891226A0 (fi) Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
BR0110610A (pt) Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
ES2091018T3 (es) Procedimiento para la deteccion de enfermedades neoplasicas.
DE69126430D1 (de) Ligand für das neu-gen-produkt
NO902319L (no) Fremgangsmaate for aa bestemme egenskaper vedroerende stroemningsdynamikk for flerfasestroemning.
AR016243A1 (es) Un anticuerpo proteico que tiene las regiones determinantes de la complementariedad del anticuerpo monoclonal f19 y que se fija especificamente a laproteina de activacion de fibroblastos; el empleo de dicho anticuerpo proteico para el tratamiento del cancer, para representar en imagenes fibroblastos
IT8220140A0 (it) Procedimento per la produzione di sostanze prodotte da cellule, particolarmente di anticorpi esimili.
ES2075016T3 (es) La subunidad alfa del receptor de adherencia a leucocitos lfa-1.
FR2661187B1 (fr) Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
WO2000050088A3 (en) Biotinylated-chemokine antibody complexes
DE69229681D1 (de) Ein protein, das spezifische dna-strukturen erkennt, und seine verwendungen
WO1997021811A3 (en) Novel tyrosine kinase receptors and ligands
Redmond et al. A serine protease (CCP1) is sequestered in the cytoplasmic granules of cytotoxic T lymphocytes.
ATE175215T1 (de) Arzneimittel für die verlängerte immunsuppression und tumorzellelimination
DE68926658D1 (de) Diagnostische gene zum nachweis von toxoplasmose
Hiramatsu et al. Unique T cell Ia antigen expressed on a hybrid cell line producing antigen-specific augmenting T cell factor.
BRPI0417575A (pt) complexo de monociclopentadienila, sistema catalisador, uso do mesmo, processos para preparar poliolefinas, e sistemas de ciclopentadieno, sistema de ciclopentadieno, e, ciclopentenona
BR0313335A (pt) Complexo de monociclopentadienila, sistema de catalisador, uso do mesmo, e, processos para preparar poliolefinas e sistemas de ciclopentadienila
EP0036336A3 (en) Process for detecting proteins specific to hypertension in mammals
NO179328C (no) Antistoffer mot retinoblastom-genprodukt, anvedelse derav samt murint hybridom
Mayet et al. A monoclonal Ro‐antibody and the serum of a Ro‐positive patient with subacute cutaneous lupus erythematosus (SCLE) react with basal layers of human epidermis
DE69631624D1 (de) Antikörper gegen menschliches restrictin
Jäckle Two‐dimensional gel analysis after removal of major proteins reveals stage‐dependent proteins in early insect development
ATE305480T1 (de) G-protein gekoppelter rezeptor

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 646182

Country of ref document: ES

FG2A Definitive protection

Ref document number: 646182

Country of ref document: ES